
Summary

STAMARiL® is indicated for active immunization against yellow fever in persons:
- travelling to, passing through or living in an area where there is a current or periodic risk of yellow fever transmission
- travelling to any country that requires an International Certificate of Vaccination for entry (which may or may not depend on the previous itinerary)
- handling potentially infectious materials (e.g. laboratory personnel).
Before you prescribe this vaccine please refer to the SmPC.1
Usage
Helps to protect against yellow fever from at least 10 days before travel for your traveller from 9 months of age1 | |||
Age | Initial dose | Booster / revaccination | Duration of protection |
From 9 months of age1, refer to current offical recommednations | 1 dose of 0.5ml of the reconstituted vaccine1 | Most do not need revaccination; refer to current offical recommednations1 | At least 10 years, may be lifelong1 |
In 2017 and 2018 we received 2 reports of fatal adverse reactions to the yellow fever vaccine (STAMARiL). Due to an increased risk of life-threatening reactions, the vaccine must not be given to anyone with a medical history of thymus dysfunction or who is immunosuppressed. In addition, extreme caution must be used and a careful risk assessment conducted before vaccination of people aged 60 years and older due to a substantially increased risk of such adverse reactions in this age group.1 |
In the most representative study in general population, the most frequently reported reactions (between 12% and 18% of subjects) were headache, asthenia, injection site pain and myalgia. In the most representative study in toddler population, the most frequently reported reactions (between 32% and 35% of toddlers) were irritability, crying and appetite loss. Adverse reactions usually occurred within the first three days following vaccination except pyrexia, which occurred between Day 4 and Day 14. For a full list of adverse reactions please refer to the product SMPC. |
.


Vaccines Masterclass Series
Enhance your travel health expertise and earn valuable CPD points.

Vaccines Masterclass Series
Enhance your travel health expertise and earn valuable CPD points.
References
- Summary of Product Characteristics Stamaril UK
MAT-XU-2301130 (v3.0) Date of preparation: May 2025